W. Sharfman

发表

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

P. LoRusso, P. Fracasso, C. Erlichman, 2005, Cancer.

A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.

Ami A. Shah, K. F. Moseley, E. Lipson, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

David C. Smith, J. Taube, M. Atkins, 2012, The New England journal of medicine.

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

C. Zahnow, S. Baylin, R. Scharpf, 2017, Cancer discovery.

A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Benjamin Izar, K. Flaherty, R. Dummer, 2017, Cancer medicine.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Israel Lowy, Mark Selby, Drew M Pardoll, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.

D. Longo, W. Alvord, M. Sznol, 1996, Journal of the National Cancer Institute.

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

J. Taube, E. Lipson, Hao Wang, 2015, Journal of Translational Medicine.

Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.

J. Taube, C. Horak, M. Atkins, 2014 .

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.

J. Taube, T. Olencki, E. Lipson, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

M. Suarez‐Almazor, M. Lacouture, I. Puzanov, 2017, Journal of Immunotherapy for Cancer.

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

C. Rudin, A. Jimeno, S. Gettinger, 2013, Clinical Cancer Research.

Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition.

Ami A. Shah, W. Sharfman, C. Bingham, 2017, Journal of immunotherapy.

BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM).

K. Flaherty, J. Sosman, M. Sznol, 2013 .

D. Longo, W. Alvord, M. Sznol, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.

D. Longo, W. Alvord, J. Janik, 1993, The New England journal of medicine.

The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin

D. Longo, W. Alvord, M. Sznol, 1993 .

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.

W. Urba, J. Janik, R. Fenton, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

J. Taube, E. Lipson, F. Hodi, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

An Open–Label, Randomized, Multi–Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin–2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma

S. Patel, G. Daniels, W. Sharfman, 2021, Oncoimmunology.

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

J. Taube, T. Olencki, E. Lipson, 2021, Journal for ImmunoTherapy of Cancer.

Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade

Ami A. Shah, E. Lipson, J. Albayda, 2017, The oncologist.

Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.

J. Taube, E. Lipson, F. Hodi, 2019 .

Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.

C. Bettegowda, E. Lipson, W. Sharfman, 2017, International journal of radiation oncology, biology, physics.

Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer.

D. Longo, W. Alvord, W. Urba, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Endocrine effects of IL-1α and β administered in a phase I trial to patients with advanced cancer

D. Longo, W. Alvord, W. Urba, 1996 .

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis

S. Brant, E. Lipson, W. Sharfman, 2017, World journal of gastroenterology.

Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma.

E. Lipson, W. Sharfman, E. Kraus, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

M. Atkins, F. Hodi, M. Smylie, 2020, Melanoma research.

22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

H. Kohrt, E. Lipson, H. Kluger, 2015 .

A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 (avb3) integrin, {+/-} dacarbazine (DTIC) in patients with metastatic melanoma (MM)

J. Sosman, J. Kirkwood, P. Hersey, 2005 .

Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors

R. Figlin, A. Belldegrun, D. Longo, 1993, Cancer.

Efficacy and outcome of Tofacitinib in Immune checkpoint inhibitor colitis.

P. Higgins, L. Fecher, W. Sharfman, 2020, Gastroenterology.

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial

J. Taube, C. Horak, M. Atkins, 2016 .

Ami A. Shah, K. F. Moseley, E. Lipson, 2018, Journal of Immunotherapy for Cancer.

A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2014 .

A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors.

J. Wolchok, B. Fox, F. Hodi, 2013 .

Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)

D. Schadendorf, U. Martens, S. Topalian, 2017 .

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.

L. Rubinstein, M. Sznol, W. Urba, 1992, Journal of the National Cancer Institute.

Has the analgesic efficacy of neurolytic celiac plexus block been demonstrated in pancreatic cancer pain?

W. Sharfman, T. Walsh, T. Walsh, 1990, Pain.

A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics.

J. Shah, M. Mihm, C. Balch, 2011, Journal of the American Academy of Dermatology.

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

J. Taube, E. Lipson, W. Sharfman, 2017, Journal of Immunotherapy for Cancer.

Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors

L. Fecher, W. Sharfman, 2015, Biologics : targets & therapy.

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

J. Larkin, F. Hodi, D. Reardon, 2017, The oncologist.

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

J. Taube, C. Drake, E. Lipson, 2012, Clinical Cancer Research.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Drew M. Pardoll, Janis M. Taube, Paul T. Nghiem, 2016, The New England journal of medicine.

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

J. Sosman, J. Kirkwood, P. Hersey, 2010, Cancer.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Ludmila V. Danilova, L. Cope, K. Kinzler, 2019, Journal of Immunotherapy for Cancer.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

V. Sondak, R. Sullivan, M. Atkins, 2018, Journal of Immunotherapy for Cancer.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

David C. Smith, J. Taube, M. Atkins, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.

Katie M. Campbell, V. Velculescu, P. Ross-Macdonald, 2020, Cancer cell.

Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).

David C. Smith, M. Atkins, J. Sosman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Interleukin 1α and Indomethacin in Treatment of Metastatic Melanoma

D. Longo, W. Alvord, M. Sznol, 1996 .

Anti-CD 3 Monoclonal Antibody Treatment of Patients with CD 3-Negative Tumors : A Phase IA / B Study 1

D. Longo, M. Sznol, Jonathan, 2006 .

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.

D. Longo, M. Sznol, W. Urba, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conditioned immune response to interferon-γ in humans

P. Duffey, D. Longo, D. Rubinow, 1999 .

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

V. Sondak, M. Atkins, J. Sosman, 2013, Nature Reviews Clinical Oncology.

Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma

W. Sharfman, H. Kaufman, T. Hughes, 2015, Cancer biology & therapy.

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

C. Berking, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.

J. Taube, C. Chung, R. Ferris, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series

E. Lipson, J. LoPiccolo, W. Sharfman, 2019, Journal of Immunotherapy for Cancer.

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting

E. Lipson, W. Sharfman, K. Bleich, 2018, Molecular oncology.

Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.

J. Taube, C. Chung, R. Ferris, 2018 .

520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358

S. Topalian, W. Sharfman, V. Boni, 2022, Annals of Oncology.

Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

C. Chung, Y. Bang, T. Meyer, 2019, Annals of Oncology.

Pediatric melanoma

C. Balch, W. Sharfman, J. Lange, 2005, Pediatric blood & cancer.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Jeffrey Weber, Keith T Flaherty, Zeynep Eroglu, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

K. Flaherty, J. Sosman, Douglas B. Johnson, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

BRAF‐V600 mutational status affects recurrence patterns of melanoma brain metastasis

C. Bettegowda, E. Lipson, W. Sharfman, 2017, International journal of cancer.

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.

E. Korn, D. Longo, M. Sznol, 2001, Blood.

Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells

C. Bettegowda, E. Lipson, W. Sharfman, 2018, Surgical neurology international.

Primary Small Cell Neuroendocrine Carcinoma of Paranasal Sinuses

J. Bishop, W. Sharfman, A. Mirrakhimov, 2014, Case reports in medicine.

Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.

K. Flaherty, R. Dummer, M. Atkins, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

J. Taube, E. Lipson, D. Pardoll, 2015, Journal of Translational Medicine.

Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM).

K. Flaherty, Douglas B. Johnson, S. Patel, 2017 .

Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.

M. Sznol, W. Urba, J. Ashwell, 1992, Cancer research.

Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.

D. Longo, M. Sznol, W. Urba, 1992, The Online journal of current clinical trials.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy

Shannon C. Trotter, J. Stein, R. Dellavalle, 2017, Melanoma management.

A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma.

R. DeJager, M. Hanna, D. Longo, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Imaging and Clinical Profile Following Concurrent Stereotactic Radiation and Immune Therapy for Melanoma Brain Metastases: Preliminary Results.

C. Bettegowda, E. Lipson, W. Sharfman, 2016, International journal of radiation oncology, biology, physics.

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

J. Taube, C. Drake, Lieping Chen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.

Katie M. Campbell, V. Velculescu, P. Ross-Macdonald, 2020, Cancer cell.

Mental neuropathy (numb chin syndrome). A harbinger of tumor progression or relapse

W. Wilson, W. Sharfman, R. Burt, 1992, Cancer.

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

J. Wolchok, F. Hodi, G. Gibney, 2016 .

A Phase II Study of Carboplatin, Cisplatin, Interferon-a, and Tamoxifen for Patients with Metastatic Melanoma

D. Longo, W. Alvord, W. Urba, 1998 .

Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T).

K. Flaherty, J. Sosman, M. Sznol, 2013 .

Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.

D. Longo, W. Alvord, M. Sznol, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Improvements in the Staging of Cutaneous Squamous-Cell Carcinoma in the 7th Edition of the AJCC Cancer Staging Manual

A. Sober, N. Liégeois, W. Sharfman, 2010, Annals of Surgical Oncology.

Abstract NG01: Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

C. Zahnow, S. Baylin, R. Scharpf, 2017 .

A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.

D. Longo, W. Alvord, W. Urba, 1998, Cancer investigation.

Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – role of smoothened inhibitors

L. Fecher, W. Sharfman, 2015 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

J. Taube, C. Drake, Lieping Chen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.